Results 201 to 210 of about 276,902 (250)

Safety and Clinical Outcomes of High‐ Versus Low‐Dose Oral Peanut Immunotherapy in Polish Children With Peanut Allergy

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aim To compare safety and clinical outcomes of two different oral immunotherapy (OIT) maintenance doses (150 mg vs. 300 mg) of peanut protein in children with peanut allergy. Methods This prospective study enrolled 44 children aged 4–17 years with confirmed peanut allergy.
Klementyna Łyżwa   +4 more
wiley   +1 more source

Factors Associated With Omalizumab Response in Chronic Spontaneous Urticaria: Are There Age‐Related Differences?

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aim This study aimed to explore clinical and laboratory markers of omalizumab response in paediatric and adult chronic spontaneous urticaria (CSU) patients. Methods The study included 32 children and 67 adults with CSU receiving omalizumab, and 29 paediatric and 30 adult healthy controls; associations with treatment response were evaluated ...
Güler Yıldırım Nalbant   +14 more
wiley   +1 more source

Systematic Review and Meta‐Analysis Suggested That Neutrophils Predominated the Airways of Children With the Respiratory Syncytial Virus

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aim The respiratory syncytial virus (RSV) is a predominant aetiology of early‐life respiratory infections. This systematic review and meta‐analysis compared the cell types involved in airways inflammation in children with and without RSV, noting that immune responses can influence long‐term complications and may involve different inflammatory ...
Muhammad Pradhika Mapindra   +8 more
wiley   +1 more source

Clinical remission in patients with severe eosinophilic asthma treated with benralizumab over 24 months: Post hoc analysis of the ANANKE study. [PDF]

open access: yesWorld Allergy Organ J
Canonica GW   +22 more
europepmc   +1 more source

Clinical Trial: Dupilumab Improves Eosinophilic Oesophagitis Outcomes Versus Placebo Regardless of Comorbidities or Treatment History in a Randomised Clinical Trial

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Dupilumab improved all histological, symptomatic, and endoscopic outcomes assessed at Week 24 versus placebo in patients with eosinophilic oesophagitis, regardless of demographics, disease characteristics, treatment history, or type 2 inflammatory disease comorbidities.
Evan S. Dellon   +7 more
wiley   +1 more source

Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A 32-Week Evaluation.

open access: yesInt Arch Allergy Immunol
Özden Ş   +8 more
europepmc   +1 more source

Unmasking EGPA with near fatal diffuse alveolar haemorrhage in severe eosinophilic asthma under treatment with benralizumab: a case report. [PDF]

open access: yesBMC Pulm Med
Drick N   +8 more
europepmc   +1 more source

Eosinophilic Oesophagitis and Incidence of Gastrointestinal Cancer: A Population‐Based Cohort Study

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Among 9115 patients with eosinophilic oesophagitis in Denmark, excess gastrointestinal cancer in the first year after diagnosis most likely reflected diagnostic work‐up. Beyond 1 year, oesophageal adenocarcinoma and hepatocellular carcinoma remained more frequent than expected; most patients with oesophageal cancer had prior Barrett's oesophagus ...
Gencer Kurt   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy